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A clinical approach to new-onset psychosis
associated with immune dysregulation: the
concept of autoimmune psychosis
Souhel Najjar1* , Johann Steiner2, Amanda Najjar3 and Karl Bechter4

Abstract: Growing data point to the overlap between psychosis and pathological processes associated with
immunological dysregulation as well as inflammation. Notably, the recent discovery of antibodies against synaptic
and neuronal cell membrane proteins such as anti-N-methyl-D-aspartate receptor provides more direct evidence
of the etiological connection between autoimmunity and subsequent hazard of psychosis. Here, we advocate the
use of term “autoimmune psychosis,” as this term suggests that autoimmune disorders can masquerade as drugresistant primary psychosis, and this subtype of psychosis has anatomical and immunological footprints in the
brain, despite the frequent absence of structural abnormalities on conventional brain MRI. Furthermore, this term
might serve as a reminder not to overlook appropriate neurological workup such as neuroimaging and EEG
testing, as well as CSF analysis, for cases with acute or subacute atypical onset of neuropsychiatric presentations
including those dominated by acute psychotic symptoms. We propose etiologically and serologically oriented
subclassification as well as multi-modal diagnostic approach to address some of the challenges inherent to early
diagnosis of patients presenting with atypical and refractory new-onset psychotic symptoms of autoimmune
origin. This is particularly relevant to the diagnosis of seronegative but probable autoimmune psychosis (SPAP)
that might masquerade as antipsychotic drug-resistant primary psychotic disorder. This distinction is
therapeutically important as autoimmune-related psychotic symptomatology can frequently respond well to
timely treatment with proper immune modulatory therapies.
Keywords: Autoimmune, Psychosis, NMDAR, Encephalitis, Neuroinflammation, Microglia, Neuronal, Synaptic,
Antibodies, Neuroimaging

Background
Human and animal data suggest that neuroinflammatory
and immunological abnormalities can contribute to the
neurobiology of primary psychotic disorders [1, 2]. Human
post-mortem brain, serological, cerebrospinal fluid (CSF),
neuroimaging, genetic, and epidemiological studies have
documented diverse inflammatory and immunological
abnormalities in a subgroup of patients diagnosed with
schizophrenia according to the currently established DSM/
ICD criteria [1–4]. Among the main inflammatory abnormalities are microglial activation and proliferation in brain
regions of functional relevance to psychosis (e.g., dorsolateral prefrontal, superior temporal, and anterior cingulate
cortices), and upregulation of inflammatory mediators such
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as pro-inflammatory cytokines and matrix metalloproteinases [1–4]. Findings of post-mortem studies have not only
linked microglial activation to the neurobiology of psychosis but also to suicidal state [3, 4]. Recent meta-analysis of
post-mortem brains documented statistically significant
increase in microglial density and pro-inflammatory gene
expression, without significant alteration in the density of
other glial cells or anti-inflammatory gene expression in
schizophrenia compared with healthy subjects [5]. Studies
documenting elevated serum levels of beta2-microglobulin
in drug-naïve schizophrenia compared with healthy
cohorts [6], with further elevation of its levels following
treatment with antipsychotic medications, [7] suggest that
immune dysregulation may play a role in a subgroup of
these patients. Various CSF immunological and inflammatory changes are also well documented in a subset of individuals with drug-resistant schizophrenia [8, 9]. These
changes include increased “CSF: serum albumin ratio”

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Najjar et al. Journal of Neuroinflammation (2018) 15:40

indicative of blood-CSF barrier hyperpermeability;
increased intrathecal synthesis of IgG, IgM, and/or IgA;
and presence of up to four IgG oligoclonal bands, mild
pleocytosis, elevated neopterin levels, and elevated cytokines [8, 9]. These observations, together with documented
elevated levels of S100B protein, a marker of glial activation
and blood-brain barrier hyperpermeability, in the brain,
CSF as well as blood support the hypothesis that hyperpermeability and/or disruption of blood-brain and blood-CSF
barriers may contribute to the neurobiology of psychosis,
in part via transendothelial inflammatory cell migration
and increased cross-talk between brain innate immunity
and peripheral adaptive immunity [1, 2, 8–10]. This is also
supported by the post-mortem ultrastructural findings of
inflammatory and degenerative changes affecting neurovascular unit in schizophrenia [1, 2].
In addition, several epidemiological studies reported a
strong bidirectional relationship between autoimmune
disorders and psychosis [2, 11]. One study showed a
positive correlation between brain-reactive antibodies associated with autoimmune disorders and subsequent
hazard of psychosis [11], although the abundance of
brain-reactive IgG antibodies in the cortex of individuals
with schizophrenia was shown in another study to be
similar to that of healthy controls [12].
Moreover, the strong association between both early
infections and increased risk of developing psychosis in
the adult life [1, 11], as well as the significant increase in
serum titers of anti-CMV and anti-HSV1 and anti-HSV2
IgG antibodies in schizophrenia patients [13], provide indirect argument in support of immune involvement [11].
Collectively, the above data point to the overlap between
psychosis and pathological processes associated with immunological dysregulation as well as inflammation.

Antibodies against neurotransmitter receptors
and synaptic proteins in schizophrenia and newonset psychosis: the concept of autoimmune
psychosis
Early identification of antibodies targeting neurotransmitter
receptors, such as 5-hydroxytryptamine 1A receptor and
muscarinic cholinergic receptor 1, as well as dopamine-2
receptor, in individuals with schizophrenia suggests that
autoimmunity plays a role in a subgroup of these patients
[14–16]. Notably, the recent discovery of antibodies against
synaptic and neuronal cell membrane proteins such as antiN-methyl-D-aspartate receptor (NMDAR) and gammaaminobutyric acid beta receptor (GABAßR) provides more
direct evidence etiologically linking autoimmunity-related
dysregulation of glutamatergic and GABAergic neurotransmissions to subsequent hazard of psychosis [17–23]. One
meta-analysis showed that patient with psychiatric illnesses
such as schizophrenia and schizoaffective disorders are
about three times more likely to have NMDAR antibodies
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(mostly of IgA or IgM type against GluN1 (NR1) subunit),
compared with healthy controls [24]. Similarly, other
studies reported higher, albeit variable, prevalence of IgG
antibodies targeting GluN1 subunit of NMDAR in the sera
of individuals with first-episode psychosis (ranging from 0
to 12%) [17–21, 25]. Furthermore, NMDAR antibody
immunofluorescence response in schizophrenia patients
with past catatonia is shown to be greater than that in
healthy controls [26]. Additional studies revealed higher
prevalence of other neuronal antibodies such as voltagegated potassium channel (VGKC)- complex antibodies in
patients with schizophrenia [27, 28]. On the contrary, the
findings from other studies provide counterargument to
the putative pathogenic significance of synaptic and neuronal antibodies in a subset of individuals with schizophrenia and new-onset psychosis. Several studies showed
comparable prevalence of antibodies targeting synaptic and
neuronal cell membrane protein among healthy and schizophrenia cohorts [20, 29]. Another recent study showed that
the prevalence of these antibodies among individuals with
first-episode psychosis was low and comparable to that of
healthy controls [30]. The mixed results and the variability
in the estimates of synaptic and neuronal antibody seropositivity may in part be attributed to methodological heterogeneity (e.g., cell-based assay (CBA) using live as
opposed to fixed cells) that might have influenced the sensitivity and specificity of immunostaining assays used across
these studies [24, 25].
The growing human and experimental data supporting
an association between autoimmunity and risk of developing psychosis have prompted some authors to use the term
“autoimmune psychosis” [17]. We advocate using the term
“autoimmune psychosis” for those autoimmune disorders
presenting primarily with atypical psychotic features masquerading as drug-resistant primary psychosis. This term
suggests that this subtype of psychosis has anatomical and
immunological footprints in the brain. It also serves as a
reminder not to overlook appropriate neurological workup,
(such as neuroimaging, EEG testing, and CSF investigation), but rather to apply it more broadly to formulate accurate differential diagnostic considerations that entertain
underlying autoimmune process among other organic etiologies. Examples of atypical psychotic presentations suggestive of organic causes [31, 32] are (1) atypical age of
onset; (2) predominance of particular symptoms such as
confusion, disorientation, and language disintegration; (3)
catatonia, given its diverse etiology; (4) predominance of
visual or multi-modal hallucinations (visual and tactile); (5)
olfactory hallucinations suggestive of mesial temporal lobe
pathology; (6) predominance of specific delusions such as
those related to misidentifications (Capgras syndrome); (7)
antecedent or concurrent medical illness or systemic manifestations including significant weight loss; and (8) lack of
predisposing risk factors for primary psychosis such as a
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strong family history of schizophrenia, a premorbid schizoid personality, or precipitating stress for mental disorder.

abnormalities such as epileptiform discharges, delta
brushes [33].

Multi-modal diagnostic approach
We recommend multi-modal diagnostic approach to
psychosis with suspected organic etiology, including immunological dysregulation, that greatly emphasize the importance of thorough clinical assessment before
considering the ever-expanding options for costly ancillary
diagnostic testing, with the main objective of augmenting
timely recognition and treatment of this unique subgroup
of psychosis. The clinical evaluation includes obtaining detailed medical and neurological history, performing thorough general and neurological examinations, recognizing
atypical psychotic presentations, and identifying clinical accompaniments suggestive of immune dysregulation after
excluding other organic causes [17, 33, 34].
The clinical accompaniments [17, 33, 34] are (1) atypical
psychotic presentation [31, 32]; (2) neurological disturbances such as rapidly evolving encephalopathy, seizures
including faciobrachial dystonic seizures pathognomonic
for limbic encephalitis associated with leucine-rich-glioma
inactivated 1 (LGI1) antibody, abnormal movements, autonomic instability, language disintegration, and reduced
level of consciousness; (3) antecedent systemic symptoms
or viral-like febrile illness suggestive of prodromal phase of
autoimmunity; (4) unexplained soft or overt findings on
neurological examination; and (5) strong personal or family
history of autoimmune disorders.
The ancillary diagnostic abnormalities suggestive of
underlying neuroimmune dysregulation [32–38] include
the followings: (1) elevated serum levels of antibodies targeting synaptic and neuronal cell membrane proteins, or
biomarker characteristic for comorbid autoimmune disorders such as systemic lupus erythematous and Hashimoto’s encephalopathy among many others; (2) CSF,
neuroimaging, and EEG abnormalities after excluding
other organic causes such as infectious etiologies: (a) CSF
abnormalities include antibodies targeting synaptic and
neuronal cell membrane proteins, lymphocytic pleocytosis, oligoclonal bands, elevated IgG index, and elevated
neopterin level (a non-specific marker of T helper cell 1
activation-dependent immune response) [35]; (b) neuroimaging structural and functional abnormalities such as
unilateral or bilateral hippocampal MRI FLAIR/T2 signal
hyperintensities suggestive of autoimmune limbic encephalitis [33], as well as hyper-, hypo-, or heterogeneous cerebral glucose metabolism on FDG- positron emission
tomography (PET) or altered cerebral blood flow on single
photon emission computed tomography (SPECT) [33, 36,
37]; we suspect that FDG hypermetabolism, as opposed to
hypometabolism, might be more indicative of inflammation after excluding alternative causes [38]; and (c) EEG

Autoimmune disorders presenting with new-onset
psychotic symptoms
We propose that psychotic presentations secondary to
immune dysfunction may be categorized into three
groups according to their specific etiology and serum
as well as CSF immunological profiles (Table 1). This
subclassification might facilitate early consideration of
these subgroups of autoimmune disorders in individuals presenting primarily with atypical new-onset
psychosis of uncertain organic causes masquerading
as refractory primary psychosis.
1. Psychosis associated with autoantibodies targeting
well-characterized synaptic and neuronal cell surface
proteins [3–5]. Indeed, findings from several case reports and clinical case series have linked autoantibodies targeting NMDAR, α-amino-3-hydroxy-5methyl-4-isoxazolepropionic acid receptor
(AMPAR), GABAßR and VGKC-protein complex, to
new-onset psychosis among other psychiatric disturbances (e.g., mania, anxiety, aggression, emotional lability, and personality changes) as the dominant
presenting symptoms [17–23, 27, 38–42]. Although
the majority of these patients eventually exhibit a
wide constellation of neurological symptoms
throughout the course of the illness, isolated neuropsychiatric symptoms with dominant psychosis may
rarely remain the key symptoms; we suggest that the
latter pattern might constitute the presentation of
milder form or forme fruste of autoimmune encephalitis. Thus, we recommend screening for these antibodies in serum and CSF of individuals presenting
with new-onset atypical drug-refractory neuropsychiatric symptoms including new-onset psychosis, particularly in those exhibiting any of the above
highlighted clinical accompaniments. This is important, as structural neuroimaging abnormalities are
commonly not noted on conventional MRI in patients with autoimmune encephalitis associated with
these synaptic and neuronal surface autoantibodies
[43, 44]. Indeed, recent studies of anti-NMDAR encephalitis showed that structural neuroimaging abnormalities are absent on initial presentation and
follow-up brain MRIs in about 89 and 79% of cases,
respectively, despite associated profound cognitive,
neurological, and neuropsychiatric disturbances [43].
Furthermore, identification of specific autoantibodies
does not only establish the diagnosis of autoimmune
psychosis, but also can clarify its subtype and guide
treatment.

Amnesia, confusion, disorientation, autonomic dysfunction,
apathy, irritability, faciobrachial dystonic seizures, and
hyponatremia
Neuromyotonia, muscle spasm, fasciculation, neuropathic
pain dysautonomia, confusion, amnesia, insomnia, and
seizures

VGKC-protein complex antibodies: LGI1 antibodies

CASPR2 antibodies

Encephalopathy, cognitive decline, memory impairment,
affective disorders, and seizures

Abbreviations: NMDAR N-methyl-D-aspartate receptor, AMPAR a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor, GABAuR gamma-aminobutyric acid beta receptor, VGK.C voltage-gated potassium channel,
LGI1 leucine-rich-glioma inactivated 1, CASPR2 contactin-associated protein-like 2, MS multiple sclerosis, ADEM acute disseminated encephalomyelitis, OCB oligoclonal band, MBP myelin basic protein, MOG myelin oligodendrocyte glycoprotein, TPO thyroid peroxidase, Tg thyroid globulin, GAD glutamic acid decarboxylase

Unknown autoantibodies
Innate- or T-cell autoimmunity?

Cognitive decline, short-term memory impairment, affective
disorders, anxiety, seizures, neuropathy, ataxia, weight loss,
cerebellar ataxia, stiff person syndrome

GAD antibodies; often associated with GABAß antibodies

Seronegative but probable autoimmune
encephalitis (SPAP)

Cognitive decline, short-term memory impairment, affective
disorders, anxiety, seizures, neuropathy, cerebellar ataxia,
and cranial neuropathy

Onconeural antibodies (HU, MA2, CRMP5, Amphyphisin

4. Autoimmune encephalitis associated with
antibodies targeting intracellular antigens

Encephalopathy, memory loss, confusion, altered level
of consciousness, seizures, stroke-like symptoms, and
myoclonus

Antithyroid antibodies:
TPO- and Tg-antibodies
Autoimmune vasculitis
Immune complex deposition

3. Hashimoto’s encephalopathy

Focal symptoms and neurological deficits, optic neuritis;
characteristic CSF analysis and brain imaging findings

OCB antibodies
Anti-myelin antibodies:
MBP-antibodies
MOG-antibodies

Inflammatory demyelinating disorders (MS, ADEM)

2. Neuroinflammatory disorders:

Neuropsychiatric systemic lupus erythematosus

1. Classical systemic autoimmune disorders:
Cognitive changes, affective disorders, anxiety, delirium,
seizures, and neurovascular disease

Seizures, memory loss, and confusion

GABAßR antibodies (IgG against B1 subunit)

NMDAR antibodies [IgG against NR2 (Glu2) subunit]
Ribosomal P antibodies

Cognitive decline, memory loss, affective changes,
confusion, agitation, delirium, and seizures

AMPAR antibodies (IgG against GluR1/2 subunits)

Psychosis associated with autoimmune and
inflammatory disorders

Cognitive decline, memory loss, speech fragmentation,
seizures, dyskinesias, catatonia, autonomic instability, and
central hypoventilation. Delta brush on EEG.

NMDAR antibodies [IgG against NR1 (Glu1) subunit]

Autoimmune encephalitis associated with synaptic
and neuronal cell membrane proteins antibodies

Associated neurological and neuropsychiatric symptoms

Autoantibodies and proposed
inflammatory mechanisms

Autoimmune Psychosis Subclass

Table 1 Etiological subclassification of autoimmune psychosis
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2. Psychosis associated with classical systemic
inflammatory and autoimmune disorders (e.g.,
neuropsychiatric systemic lupus erythematosus),
neuroinflammatory disorders (e.g., inflammatory
demyelinating disorders such as multiple sclerosis and
acute disseminated encephalomyelitis, and
neurosarcoidosis), Hashimoto’s encephalopathy, or
autoantibodies targeting intracellular antigens (i.e.,
glutamic acid decarboxylase and onconeuronal
antigens).
Neuropsychiatric systemic lupus erythematous
(NPSLE) occurs in 25 to 75% of SLE patients [1].
NPSLE includes cognitive deficit, headache,
psychiatric symptoms (e.g., anxiety, depression, and
psychosis), seizures, movement disorders, nonspecific demyelination, and cerebrovascular events
[32, 45, 46]. Psychiatric symptoms often occur
within the first 2 years of disease onset [1] and are
rarely limited to isolated psychosis [32]. The pathophysiology of NPSLE is multifactorial and includes
inflammation-mediated microangiopathy and autoantibodies such as anti-GluN2 (NR2) subunits of
NMDAR, anti-ribosomal P (positive in 90% of
psychotic SLE patients), anti-endothelial cell, antiganglioside, and anti-dsDNA, as well as antiphospholipid antibodies [1]. Other systemic
inflammatory disorders such as Sjögren’s syndrome,
vasculitis, and Behçet’s disease can also present with
a variety of neuropsychiatric features including
psychosis, in addition to a wide constellation of
neurological disturbances such as cognitive changes
[18]. Please refer to the comprehensive review
published on this topic [18].
Central nervous system (CNS) inflammatory
demyelinating disorders such as acute disseminated
encephalomyelitis [47] and multiple sclerosis [48]
can present with diverse psychotic features,
suggesting that these disorders may share some
common immune and inflammatory mechanisms
with primary psychotic disorders [49].
Neurosarcoidosis is another neuroinflammatory
disorder that can have neuropsychiatric
comorbidities with psychotic features. Indeed,
psychotic manifestations can be seen in up to 17% of
individuals with neurosarcoidosis [50].
Hashimoto’s encephalopathy is a relatively
uncommon steroid-responsive encephalopathy. It is
characterized by rapidly progressive non-specific
encephalopathy, seizures, myoclonus, stroke-like
episodes, and diverse neuropsychiatric features that
include mood disorders as well as psychosis [33].
This disorder is associated with thyroid antibodies,
which can are also present in about 13% of healthy
individuals [33]. Brain MRI and CSF investigations
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may be normal or revealing non-specific abnormalities [33].
Glutamic acid decarboxylase antibody seropositivity
has been associated with a variety of neurological
disorders including limbic encephalitis, which
typically present with neurological (e.g., cognitive,
short-term memory impairment, confusion, seizures)
and psychiatric symptoms (mood alteration, anxiety,
psychosis) [1, 33]. However, studies that are more
recent indicated that other concomitant antibodies,
such as those targeting GABAßR, are more likely to be
the culprit [51, 52].
Paraneoplastic limbic systems can also present with a
variety of neuropsychiatric including psychosis and
neurological symptoms such as seizures and cognitive
impairment [33]. Although onconeuronal antibodies
are associated with paraneoplastic CNS syndromes,
direct cytotoxic effects of T cell immunity appear to
be more etiologically relevant to pathophysiology of
paraneoplastic limbic encephalitis [53].

3. Seronegative but probable autoimmune psychosis
(SPAP). The evidence supporting the relevance of
SPAP as a distinct diagnostic category in clinical
practice is indirect, limited, and largely consists of
case reports that document responsiveness of
secondary psychosis to immune therapies despite
negative comprehensive serological assays for
systemic and central nervous system autoimmune
diseases, as well as lack of any other discernable
organic etiology [54, 55]. The molecular and cellular
changes of the pathoimmunological processes
underlying SPAP remain largely mysterious.
However, some of these cases may represent a
subgroup of the increasingly recognized spectrum of
seronegative autoimmune encephalitides [33, 50,
54–61] presenting primarily with acute or subacute
onset encephalopathy, short-term memory impairment, and neuropsychiatric features with dominant
psychotic symptoms [54, 55]. Its etiological connection to the underlying immunological dysregulation
can be inferred only after excluding other alternative
organic causes such as infectious, toxic-metabolic,
substance abuse, neurodegenerative, or genetic
disorders. We suggest that seronegativity is likely
attributed to autoantibodies that either have not yet
been discovered or present exclusively in the CSF
that is often not analyzed in this subgroup of individuals; (I) many cases of paraneoplastic limbic
encephalitis previously characterized as seronegative
were subsequently found to be GABAßR antibody
seropositive [52], and (II) NMDAR antibodies were
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detected only in CSF of about 13% of individuals
with confirmed anti-NMDAR encephalitis through
research-based combined testing of immunohistochemistry and CBAs [62]. The strong immunoprecipitation property of the brain can also result in
high binding of autoantibodies to their respective
receptors, thus limiting their free circulation and
detection in the serum and CSF [63]. Furthermore,
methodological heterogeneity might occasionally
contribute to false seronegativity; although the
current CBA testing using commercially available
kits is very specific, it appears to be less sensitive for
detecting antibodies targeting synaptic and neuronal
cell surface antigens (e.g., NMDAR, GABAßR,
AMPAR) in patients with suspected synaptic autoimmune encephalitis, as compared to research-based
combined testing of both rodent brain immunohistochemical staining as well as CBAs [64]. Indeed,
about 12% of all confirmed autoimmune encephalitis
cases were identified only after demonstrating
positive rodent brain reactivity on immunohistochemical staining followed by research-based CBAs
[64]. Alternatively, CNS autoimmunity may be
mediated by not-yet-defined innate- or T cell
autoimmunity, instead of circulating autoantibodies
[1]. Thus, diagnosing SPAP requires high index of
clinical suspicion together with lower threshold for
referring patients with suspected SPAP for basic
diagnostic investigation such as neuroimaging, EEG
testing, and CSF analysis. However, given the relatively low diagnostic yield of conventional brain MRI
[43, 44] and the limited use of CSF analysis, it is
conceivable that SPAP frequently escapes clinical detection. Indeed, findings from recent studies assessing the sensitivity of various diagnostic tests in
autoimmune encephalitis indicate that brain FDGPET offers a higher diagnostic yield, with cerebral
cortical hypometabolism being the most frequently
observed abnormality, compared with early EEG,
conventional brain MRI, and even CSF analysis [65].
A clinically meaningful response to immune therapy
trial, similar to the approach used in seronegative
rheumatologic disorders [66], might provide indirect
evidence of the underlying CNS autoimmunity, particularly when associated with restoration of functional neuroimaging abnormalities of glucose
metabolism or blood flow following immune therapy
[36, 67, 68]. The yield of brain biopsy, similar to that
of autoimmune encephalitis, is likely low [41]. However, brain biopsy might be considered in carefully
selected cases of severe encephalopathy associated
with refractory psychotic features of undefined
organic causes to confirm their etiological connection to autoimmunity before initiating more
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aggressive immunosuppressive therapies. Indeed, we
have reported cases and reviewed literature of brain
biopsy-proven seronegative autoimmune encephalitis
presenting with isolated neuropsychiatric disorders including psychosis [54, 56]. Although the typical neuroinflammatory findings of perivascular and
parenchymal mononuclear inflammatory infiltrates
and/or microglial nodules are typically not etiologically
specific, but can, in the proper clinical context and after
excluding other organic etiologies such as infections,
provide indirect evidence of probable neuroimmune
process.

Conclusions and future directions
We believe that the suggested etiologically and serologically oriented subclassification as well as the multi-modal
diagnostic approach might address some of the challenges
inherent to early diagnosis of patients presenting with
atypical drug-resistant new-onset psychosis with suspected link to immune dysregulation. This is particularly
relevant to the diagnosis of SPAP that might masquerade
as antipsychotic drug-resistant primary psychotic disorder.
This distinction is also therapeutically important as
autoimmune-related psychotic symptomatology can frequently respond well to timely treatment with proper immune modulatory therapies. However, building broader
consensus evidence-based guidelines highlighting costefficient diagnostic workup and management of patients
presenting with unusual new-onset psychotic symptoms
with suspected autoimmune origin such as SPAP are warranted. Large-sample randomized clinical trials investigating the prevalence of autoimmune psychosis among
individuals with new-onset psychosis are needed. The trial
designs need to incorporate more CSF studies and more
advanced multi-modal neuroimaging such as resting-state
functional brain MRI for elucidating potentially characteristic neural network functional connectivity alterations
[44] as well as PET utilizing a novel translocator protein
(TSPO) radioligand for imaging microglia activationmediated neuroinflammation [69].
Abbreviations
AMPAR: α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor;
CBA: Cell-based assay; CNS: Central nervous system; CSF: Cerebrospinal fluid;
GABAßR: Gamma-aminobutyric acid beta receptor; GAD: Glutamic acid
decarboxylase; LGI1: Leucine-rich-glioma inactivated 1; NMDAR: N-Methyl-Daspartate receptor; SPAP: Seronegative but probable autoimmune psychosis;
TSPO: Translocator protein; VGKC-protein complex: Voltage-gated potassium
channel
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